These documents matter because they prove there is no legal barrier to the health minister directing the PBAC in how it applies the cost-effectiveness framework and that, in fact, this exercise of power is critical to achieving real change.
The minister exercised their power, the PBAC welcomed it, and the system changed
January 9, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
OncoSil charts a new growth phase as Chairman outlines progress and opportunities
November 19, 2025 - - Latest News -
CSL unveils US expansion, cementing its position as a global biopharma leader
November 19, 2025 - - Latest News -
Cleo Diagnostics appoints U.S. oncologist as first key opinion leader
November 19, 2025 - - Australian Biotech -
IDT Australia resets strategy as advanced therapies drive new phase of growth
November 19, 2025 - - BioPharma -
Dimerix Phase 3 kidney trial clears seventh safety review
November 19, 2025 - - Australian Biotech -
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 - - Australian Biotech -
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech